{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:48:32Z","timestamp":1793152112097,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40263-022-00941-1","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T04:02:54Z","timestamp":1660276974000},"page":"995-1005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"36","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"issue":"8","key":"941_CR1","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","volume":"55","author":"A Govoni","year":"2018","unstructured":"Govoni A, Gagliardi D, Comi GP, et al. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol. 2018;55(8):6307\u201318.","journal-title":"Mol Neurobiol"},{"key":"941_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11\u201325.","journal-title":"Appl Clin Genet"},{"key":"941_CR3","unstructured":"US Library of Medicine. Genetics Home Reference: spinal muscular atrophy. 2020. http:\/\/ghr.nlm.nih.gov\/condition\/spinal-muscular-atrophy. Accessed 27 Jun 2022."},{"issue":"1","key":"941_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis."},{"key":"941_CR5","unstructured":"National Institute for Health Research. AVXS-101 for spinal muscular atrophy. 2018. http:\/\/www.io.nihr.ac.uk\/report\/avxs-101-for-spinal-muscular-atrophy\/. Accessed 28 Jun 2022."},{"key":"941_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","volume":"28","author":"J Kirschner","year":"2020","unstructured":"Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38\u201343.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"941_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Alias L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"16","key":"941_CR8","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.3390\/ijms22169029","volume":"22","author":"M Costa-Roger","year":"2021","unstructured":"Costa-Roger M, Blasco-Perez L, Cusco I, et al. The importance of digging into the genetics of SMN genes in the therapeutic scenario of spinal muscular atrophy. Int J Mol Sci. 2021;22(16):9029.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"941_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.27363","volume":"64","author":"EA Kichula","year":"2021","unstructured":"Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64(4):413\u201327.","journal-title":"Muscle Nerve"},{"issue":"12","key":"941_CR10","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/s41431-019-0415-4","volume":"27","author":"C Serra-Juhe","year":"2019","unstructured":"Serra-Juhe C, Tizzano EF. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. Eur J Hum Genet. 2019;27(12):1774\u201382.","journal-title":"Eur J Hum Genet"},{"key":"941_CR11","unstructured":"Novartis Gene Therapies. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion: US prescribing information. 2021. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/zolgensma.pdf. Accessed 28 Jun 2022."},{"key":"941_CR12","unstructured":"Novartis Pharmaceuticals Canada. ZOLGENSMA\u00ae (onasemnogene abeparvovec) solution for intravenous infusion: Canadian product monograph. 2021. https:\/\/pdf.hres.ca\/dpd_pm\/00061728.PDF. Accessed 28 Jun 2022."},{"key":"941_CR13","unstructured":"European Medicines Agency. Zolgensma (onasemnogene abeparvovec) solution for infusion: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zolgensma-epar-product-information_en.pdf. Accessed 28 Jun 2022."},{"key":"941_CR14","unstructured":"Novartis Gene Therapies. Zolgensma (onasemnogene abeparvovec): Japanese prescribing information: Novartis Gene Therapies; 2021."},{"issue":"11","key":"941_CR15","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/mt.2011.157","volume":"19","author":"AK Bevan","year":"2011","unstructured":"Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011;19(11):1971\u201380.","journal-title":"Mol Ther"},{"issue":"1","key":"941_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59\u201365.","journal-title":"Nat Biotechnol"},{"key":"941_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen G, Burghes AHM, Hsieh C, et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med. 2021;27:1701\u201311.","journal-title":"Nat Med"},{"issue":"18","key":"941_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"941_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"10","key":"941_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341.","journal-title":"Lancet Neurol"},{"issue":"7","key":"941_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"941_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137.","journal-title":"Nat Med"},{"key":"941_CR23","unstructured":"US FDA. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi): summary basis for regulatory action. 2019. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma. Accessed 28 Jun 2022."},{"key":"941_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","volume":"98","author":"LP Lowes","year":"2019","unstructured":"Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1\/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39\u201345.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"941_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54(2):179\u201385.","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"941_CR26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341.","journal-title":"JAMA Neurol"},{"key":"941_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","volume":"118","author":"SE Matesanz","year":"2021","unstructured":"Matesanz SE, Battista V, Flickinger J, et al. Clinical experience with gene therapy in older patients with spinal muscular atrophy. Pediatr Neurol. 2021;118:1\u20135.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"941_CR28","doi-asserted-by":"publisher","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","volume":"146","author":"MA Waldrop","year":"2020","unstructured":"Waldrop MA, Karingada C, Storey MA, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146(3):e20200729.","journal-title":"Pediatrics"},{"key":"941_CR29","doi-asserted-by":"crossref","unstructured":"Yang M, Georgieva M, Wu E, et al. Outcomes of single-agent onasemnogene abeparvovec or nusinersen, and of nusinersen switching to onasemnogene abeparvovec, in patients with spinal muscular atrophy: results of a provider survey in the United States [abstract no. 2346]. Neurology. 2021;96(15 Suppl.).","DOI":"10.1212\/WNL.96.15_supplement.2346"},{"key":"941_CR30","doi-asserted-by":"crossref","unstructured":"Dabbous O, Yang M, Georgieva M, et al. Real-world outcomes of nusinersin alone and onasemnogene abeparvovec (OA) alone or with prior nusinersin in pediatric patients with spinal muscular atrophy (SMA): interim analysis of a US retrospective chart review study [abstract no. P18.002]. In: American Academy of Neurology Annual Meeting. 2022.","DOI":"10.1212\/WNL.98.18_supplement.1165"},{"key":"941_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","volume":"28","author":"HG Ali","year":"2021","unstructured":"Ali HG, Ibrahim K, Elsaid MF, et al. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther. 2021;28:676\u201380.","journal-title":"Gene Ther"},{"issue":"2","key":"941_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","volume":"8","author":"J Friese","year":"2021","unstructured":"Friese J, Geitmann S, Holzwarth D, et al. Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec\u2014a single centre experience. J Neuromuscul Dis. 2021;8(2):209\u201316.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"941_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Weiss","year":"2022","unstructured":"Weiss C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6(1):17\u201327.","journal-title":"Lancet Child Adolesc Health."},{"key":"941_CR34","unstructured":"Chroscinska-Krawczyk M, Zienkiewicz E. Application of gene therapy in patients with spinal muscular atrophy - own experience [abstract no. 93]. Dev Med Child Neurol. 2021;63(Suppl. 2):58."},{"issue":"3","key":"941_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D'Silva","year":"2022","unstructured":"D\u2019Silva AM, Holland S, Kariyawasam D, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9(3):339\u201350.","journal-title":"Ann Clin Transl Neurol"},{"key":"941_CR36","doi-asserted-by":"crossref","unstructured":"Servais L, De Vivo D, Kirschner J, et al. Effectiveness and safety of onasemnogene abeparvovec in older patients with spinal muscular atrophy (SMA): real-world outcomes from the RESTORE registry [abstract no. S39.002]. In: American Academy of Neurology Annual Meeting. 2022.","DOI":"10.1212\/WNL.98.18_supplement.984"},{"key":"941_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2022.05.001","volume":"132","author":"DH Chand","year":"2022","unstructured":"Chand DH, Mitchell S, Sun R, et al. Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a Global Managed Access Program. Pediatr Neurol. 2022;132:27\u201332.","journal-title":"Pediatr Neurol"},{"issue":"10","key":"941_CR38","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","volume":"44","author":"JW Day","year":"2021","unstructured":"Day JW, Mendell JR, Mercuri E, et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug Saf. 2021;44(10):1109\u201319.","journal-title":"Drug Saf"},{"issue":"3","key":"941_CR39","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):560\u20136.","journal-title":"J Hepatol"},{"issue":"3","key":"941_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"941_CR41","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","volume":"35","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2021;35(12):1317\u201328.","journal-title":"CNS Drugs"},{"key":"941_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","volume":"36","author":"J Paik","year":"2022","unstructured":"Paik J. Risdiplam: a review in spinal muscular atrophy. CNS Drugs. 2022;36:401\u201310.","journal-title":"CNS Drugs"},{"key":"941_CR43","unstructured":"National Instute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy: highly specialised technologies guidance [HST15]. 2021. https:\/\/www.nice.org.uk\/guidance\/hst15. Accessed 28 Jun 2022."},{"issue":"6","key":"941_CR44","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","volume":"31","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Vrscaj E, Servais L, et al. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021;31(6):574\u201382.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"941_CR45","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestree N, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24(7):930\u201340.","journal-title":"Nat Neurosci"},{"issue":"4","key":"941_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(21)00071-5","volume":"20","author":"N Goemans","year":"2021","unstructured":"Goemans N. Gene therapy for spinal muscular atrophy: hope and caution. Lancet Neurol. 2021;20(4):251\u20132.","journal-title":"Lancet Neurol"},{"issue":"2","key":"941_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-190451","volume":"7","author":"RS Finkel","year":"2020","unstructured":"Finkel RS, Day JW, De Vivo DC, et al. RESTORE: a prospective multinational registry of patients with genetically confirmed spinal muscular atrophy\u2014rationale and study design. J Neuromuscul Dis. 2020;7(2):145\u201352.","journal-title":"J Neuromuscul Dis."},{"key":"941_CR48","doi-asserted-by":"crossref","unstructured":"Hodgkinson-Brechenmacher V, Oskoui M, Brais B, et al. The Canadian neuromuscular disease registry: a national spinal muscular atrophy (SMA) registry for real world evidence [abstract no. EP.262]. Neuromuscul Disord. 2021;31(Suppl. 1):S129.","DOI":"10.1016\/j.nmd.2021.07.287"},{"issue":"1","key":"941_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann A, Konig K, Bernert G, et al. SMArtCARE\u2014a platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14(1):18.","journal-title":"Orphanet J Rare Dis"},{"key":"941_CR50","doi-asserted-by":"crossref","unstructured":"Gomez-Garcia de la Banda M, Grimaldi-Bensouda L, Urtizberea J, et al. Registry - SMA France: one year after launching the national French registry on SMA [abstract no. EP.267]. Neuromuscul Disord. 2021;31(Suppl. 1):S130-S1.","DOI":"10.1016\/j.nmd.2021.07.292"},{"issue":"1","key":"941_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1051\/medsci\/2021187","volume":"37","author":"M Lemoine","year":"2021","unstructured":"Lemoine M, Gomez M, Grimaldi L, et al. Le registre national SMA France: des r\u00e9sultats d\u00e9j\u00e0 encourageants. Med Sci (Paris). 2021;37(1):25\u20139.","journal-title":"Med Sci (Paris)"},{"issue":"10","key":"941_CR52","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","volume":"37","author":"M Bischof","year":"2021","unstructured":"Bischof M, Lorenzi M, Lee J, et al. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin. 2021;37(10):1719\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"941_CR53","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther. 2019;36(5):1164\u201376.","journal-title":"Adv Ther"},{"key":"941_CR54","unstructured":"Finkel RS, Dabbous O, Droege M, et al. An indirect comparison of time to treatment effect in spinal muscular atrophy type 1 (SMA1) [abstract no. EPR2046]. Eur J Neurol. 2019;26(Suppl. 1):223."},{"issue":"3","key":"941_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ana.26299","volume":"91","author":"CJJ Yeo","year":"2022","unstructured":"Yeo CJJ, Simmons Z, De Vivo DC, et al. Ethical perspectives on treatment options with spinal muscular atrophy patients. Ann Neurol. 2022;91(3):305\u201316.","journal-title":"Ann Neurol"},{"issue":"1","key":"941_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/08830738211040292","volume":"37","author":"S Deng","year":"2022","unstructured":"Deng S, Lee BH, Ciafaloni E. Parent perceptions in choosing treatment for infants with spinal muscular atrophy diagnosed through newborn screening. J Child Neurol. 2022;37(1):43\u20139.","journal-title":"J Child Neurol"},{"issue":"10","key":"941_CR57","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/1060028020914274","volume":"54","author":"D Stevens","year":"2020","unstructured":"Stevens D, Claborn MK, Gildon BL, et al. Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother. 2020;54(10):1001\u20139.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"941_CR58","doi-asserted-by":"publisher","first-page":"1843277","DOI":"10.1080\/20016689.2020.1843277","volume":"8","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Kulas S, et al. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020;8(1):1843277.","journal-title":"J Mark Access Health Policy."},{"issue":"1","key":"941_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"941_CR60","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841.","journal-title":"J Mark Access Health Policy."},{"key":"941_CR61","doi-asserted-by":"crossref","unstructured":"Malone DC, Arjunji R, Dean R, et al. The value of onasemnogene abeparvovec (AVXS-101) as a cost-effective gene replacement therapy for spinal muscular atrophy type 1 in improving survival, healthcare resource utilization, and motor function [abstract no. PBI1]. Value Health Reg Issues. 2019;19(Suppl.):S11.","DOI":"10.1016\/j.vhri.2019.08.057"},{"issue":"1","key":"941_CR62","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484.","journal-title":"J Mark Access Health Policy."},{"issue":"6","key":"941_CR63","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2020.09.021","volume":"24","author":"TF Broekhoff","year":"2021","unstructured":"Broekhoff TF, Sweegers CCG, Krijkamp EM, et al. Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24(6):759\u201369.","journal-title":"Value Health."},{"issue":"12","key":"941_CR64","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih ST, Farrar MA, Wiley V, et al. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92(12):1296\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"941_CR65","doi-asserted-by":"crossref","unstructured":"Dean R, Miller B, Arjunji R, et al. Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan [abstract no. PMU36]. Value Health. 2020;23(Suppl. 1):S239.","DOI":"10.1016\/j.jval.2020.04.810"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00941-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:05:40Z","timestamp":1727769940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00941-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00941-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"11 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}